Fate Therapeutics Stock News

In the last trading session, 1.08 million shares of the Fate Therapeutics Inc. (NASDAQ:FATE) were traded, and its beta was 1.45. Most recently the company’s share price was $52.19, and it changed around -$0.26 or -0.50% from the last close, which brings the market valuation of the company to $4.90B. FATE currently trades at a … Fate Therapeutics Inc. (NASDAQ: FATE): The Stock We Should Bet On For Economic Growth In The Months To Come Read More »

The trading price of Fate Therapeutics Inc. (NASDAQ:FATE) closed lower on Monday, November 22, closing at $52.45, -6.29% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

Related Stocks: FATE ,

Wall Street analysts expect that Fate Therapeutics, Inc. (NASDAQ:FATE) will post $13.99 million in sales for the current fiscal quarter, Zacks reports. Eight analysts have made estimates for Fate Therapeutics earnings. The highest sales estimate is $30.00 million and the lowest is $5.00 million. Fate Therapeutics posted sales of $15.90 million during the same quarter []

Global NK Cell Therapy Market report 2021 focuses on the industry status, future forecast, growth opportunity, key market, and key players. This study is very useful information for new and growing companies to display themselves in the market. Additionally, the

Invesco Ltd. boosted its stake in Fate Therapeutics, Inc. (NASDAQ:FATE) by 30.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 884,134 shares of the biopharmaceutical companys stock after buying an additional 206,998 shares during the quarter. Invesco Ltd.s holdings in Fate Therapeutics []

SAN DIEGO, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the developm

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q3 2021 Results - Earnings Call Transcript

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 1.72% and 64.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for

Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.

Catherine Wood (Trades, Portfolio) disclosed last week her firm, ARK Investment Management, made a number of changes to its portfolio in August.

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for

The positive results the company announced after the bell yesterday didn't meet some lofty expectations.